The application of approved anti-PD-1 antibodies in melanoma treatment has gained revolutionary progress in prolonging the patients’ prognosis.56 Nevertheless, low response rate and treatment resistance pose an obstacle in the path of improving the durable effect.57,58 Tumorous PD-L1 expression is tightly related to immunotherapy efficacy in melanoma,59 but the exact role remains controversial. This evidence concerns the gene CD274 and melanoma.